Loading...
DERM
XNAS
Market cap93mUSD
Nov 20, Last price  
3.30USD
1D
-7.04%
1Q
-57.42%
IPO
-63.33%
Name

Journey Medical Corp

Chart & performance

D1W1MN
XNAS:DERM chart
P/E
—
P/S
1.51
EPS
—
Vol. 1Y
70.61%
Shs. 5Y
8.02%
Rev. 5Y
6.79%
Div Yld LY
—
Div Yld TTM
—
Revenues
62m
+10.20%
7,300,0007,300,00022,585,0004,541,00042,339,00034,921,00044,531,00063,134,00073,669,00079,181,00056,134,00061,858,000
Net income
-11m
L-22.09%
-31,875,000-78,399,000-89,084,000-303,261,000-221,540,0003,625,0005,283,000-43,994,000-29,628,000-3,853,000-14,672,000-11,431,000
CFO
-12m
L+36.31%
-31,404,000-48,442,000-74,111,000-103,963,000-213,098,0009,018,0005,132,000-2,181,000-13,534,0005,240,000-9,127,000-12,441,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.

Key people

Executive Chairman of the Board · since 2014
Claude Maraoui
President, Chief Executive Officer, Director · since 2021
Ramsey Alloush
Chief Operating Officer, General Counsel · since 2025
Joseph Benesch
Chief Financial Officer, Corporate Controller · since 2024
Michael Pearce
Director · since 2024
Independent Director · since 2021
Justin Smith
Independent Director · since 2021
Independent Director · since 2021
IPO date
Nov 12, 2021
Employees
20
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT